Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Launched by UNIVERSITY OF PITTSBURGH · Jan 31, 2025
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help doctors identify patients who are at a higher risk of opioid overdose. Researchers are using a computer program that analyzes health records to flag patients who may need extra attention when it comes to their opioid prescriptions. The trial will compare two approaches: one that includes helpful reminders for doctors (called nudges) and one that follows the usual care without these reminders. The main goal is to make prescribing safer and lower the chances of an overdose.
To participate in this study, individuals must be at least 18 years old and have received an opioid prescription in the past year. They should also have visited a primary care doctor within that time. However, those who have been diagnosed with certain serious illnesses, like cancer, or who are receiving hospice care are not eligible. If you join the study, you can expect to help researchers understand how these nudges might improve patient safety when it comes to opioid use. This could ultimately lead to better care for individuals at risk of overdose.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Received an opioid prescription within the past year
- • Age 18 years or older at the time of the opioid prescription
- • At least one visit to an internal medicine or family care practice within the past year
- Exclusion Criteria:
- • Diagnosis of malignant cancer within the past year
- • Enrollment in hospice care
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Walid F Gellad, MD, MPH
Principal Investigator
University of Pittsburgh Center for Pharmaceutical Policy and Prescribing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported